Free Trial
NASDAQ:ACB

Aurora Cannabis Q1 2026 Earnings Report

Aurora Cannabis logo
$4.49 -0.20 (-4.26%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.50 +0.01 (+0.33%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis EPS Results

Actual EPS
N/A
Consensus EPS
$0.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Aurora Cannabis Revenue Results

Actual Revenue
N/A
Expected Revenue
$96.83 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aurora Cannabis Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Aurora Cannabis Earnings Headlines

ACB - Aurora Cannabis Inc Key Metrics - Morningstar
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Aurora Cannabis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aurora Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurora Cannabis and other key companies, straight to your email.

About Aurora Cannabis

Aurora Cannabis (NASDAQ:ACB) (NASDAQ:ACB) is a Canada‐based licensed producer of medical and recreational cannabis products. The company cultivates, processes and distributes a wide range of flower, oils, capsules and derivative products under several in-house brands. Aurora operates multiple production facilities in Alberta, including its flagship Aurora Sky and Aurora Sun greenhouses, as well as international cultivation sites and processing facilities in Europe, Latin America and Australia.

Since its founding in 2013, Aurora has grown through a combination of organic investment in controlled-environment facilities and strategic acquisitions of licensed operators. Its vertical integration strategy spans cultivation, research and development, extraction and manufacturing, enabling it to bring pharmaceutical-grade products to market. The company has pursued GMP certification for many of its facilities, underscoring its focus on consistency, quality control and regulatory compliance for medical patients and recreational consumers alike.

In addition to dried flower and oils, Aurora develops edibles, beverages and skincare products designed to meet diverse consumer needs. The company has also established contract cultivation and tolling partnerships, leveraging its production expertise and proprietary genetics to support other licensed producers and research institutions. Aurora’s supply chain network serves markets across North America and Europe, with distribution agreements in Germany, the United Kingdom, Italy and other regulated jurisdictions.

Aurora’s executive team is led by President and Chief Executive Officer Miguel Martin, who joined the company in 2019 after a career in consumer-packaged goods and global operations. The board of directors includes industry veterans and former public-health officials, reflecting Aurora’s dual focus on commercial growth and responsible stewardship. Under this leadership, Aurora continues to refine its operational footprint, expand product offerings and pursue sustainable practices in an evolving cannabis landscape.

View Aurora Cannabis Profile

More Earnings Resources from MarketBeat